

To the members of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)  
Program of the AG Experimental Dermato-Oncology 2025

Thursday 13.03.2025, 9:00-12:00  
Room: Please see ADF "Hauptprogramm"

**8:55 Welcome Address**

Evelyn Gaffal & Alpaslan Tasdogan (Lübeck, Essen)

- 9:00-9:15 Preclinical evaluation of immune checkpoint inhibitor avelumab combined with DC-based vaccination for the treatment of Merkel cell carcinoma**  
F. Bremm, T. Sauerer, A. Beenken, L. Heger, D. Dudziak, N. Bosch, M. Erdmann, C. Berking, N. Schaft, J. Doerrle (Erlangen, Augsburg, Erlangen, Deutschland, Jena)
- 9:15-9:30 Investigation of the anti-tumor humoral immune response in patients with skin cancers by antigens identification and B cell receptor sequencing**  
P. Li, T. Sinnberg, T. Etterlin, O. Pop , K. Hofmeister, H. Niessner, V. Walter, M.-T. Abdou, M. Kilic, L. Strohbehn, A. Nübling, S. Mane, B. Balciunaite, M. Reitmajer, L. Flatz (Tuebingen, Berlin, St. Gallen)
- 9:30-9:45 AHR-deficient tumour cells escape CD8+ T cell immune therapy**  
S. Gellert, B. Kruse, A. Buzzai, M. Celebi, W. Li, K. Knauth, S. Bonifatius, M. von Wricz Rekowski, M. Boettcher, S. Weinert, M. Mengoni, A. Braun, D. Mougiakakos, T. Tueting (Magdeburg)
- 9:45-10:00 Novel metabolic vulnerabilities in metastatic melanoma**  
F. Cansiz, L. Nascentes Melo, G. Allies, J. Roesler, S. Meckelmann, A. Tasdogan (Essen)
- 10:00-10:30 Coffee break**
- 10:30-10:45 DIRAS1 overexpression reduces tumor burden in a murine multistage chemical skin carcinogenesis model by decreasing the activity of RAS**  
P. Meisel, T. Kolbe, M. Dahlhoff (Vienna, Tulln)
- 10:45-11:00 An investigation of melanoma immunity using single-cell multiomics: Novel cell-cell communication partners and their antitumoral role**  
A. Stubenvoll, M. Schmidt, J. Moeller, M. Lingner Chango, C. Schultz, O. Antoniadou, H. Loeffler-Wirth, S. Bernhart, F. Grosse, B. Thier, A. Paschen, C. Schoeder, H. Binder, M. Kunz (Leipzig, Essen)
- 11:00-11:45 TCR-engineered T cells for adoptive therapy of cancer**  
Prof. Matthias Leisegang (Chicago)